Cargando…
Advanced ovarian cancer treated in pregnancy and detected by cell-free DNA aneuploidy screening
• Abnormal cell free DNA results may indicate occult maternal malignancy. • Cesarean-cytoreductive surgery is feasible even with significant disease burden. • Carboplatin/paclitaxel is first line for epithelial ovarian cancer in pregnancy.
Autores principales: | Cordeiro Mitchell, Christina N., Murdock, Tricia, Fader, Amanda N., Stone, Rebecca L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003407/ https://www.ncbi.nlm.nih.gov/pubmed/29915798 http://dx.doi.org/10.1016/j.gore.2018.03.006 |
Ejemplares similares
-
Cell-free DNA screening for aneuploidies in 7113 pregnancies: single Italian centre study
por: Mesoraca, Alvaro, et al.
Publicado: (2020) -
Cell-free DNA screening for sex chromosomal aneuploidies in 9985 pregnancies: Italian single experience
por: Margiotti, Katia, et al.
Publicado: (2020) -
Targeted fetal cell‐free DNA screening for aneuploidies in 4,594 pregnancies: Single center study
por: Koc, Altug, et al.
Publicado: (2019) -
Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis
por: Fairbrother, Genevieve, et al.
Publicado: (2016) -
Multisite assessment of the impact of cell-free DNA-based screening for rare autosomal aneuploidies on pregnancy management and outcomes
por: Mossfield, Tamara, et al.
Publicado: (2022)